Drug intelligence / Profile preview

RENUBI G

Development stage: Unknown
Lead developer: PICO Entech
Administration: Oral

Overview

RENUBI G is a health supplement developed by PICO Entech, formulated as a combination of aldehyde dehydrogenase (ALDH) dried yeast and Ginkgo biloba leaf extract. It is marketed for the improvement of blood circulation and memory enhancement. The product leverages PICO Entech's proprietary ALDH technology, which utilizes the enzymatic activity of aldehyde dehydrogenase to metabolize aldehydes, combined with the established circulatory and cognitive benefits of Ginkgo biloba. It is positioned as a functional health food in the South Korean market.

Brand names: RENUBI G리뉴비 지
Other names: 리뉴비 지

Targets

ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)

Beyond the preview

Go deeper on RENUBI G.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RENUBI G.

Explore the full profile